Recruiting Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer NCT07471776 Conditions Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer ( HER2 Negative), +4 more Locations Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China Fudan University Shanghai Cancer Center — Shanghai, China View Trial Details
Recruiting Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer NCT07193394 Conditions Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer ( HER2 Negative), +9 more Locations Polyclinique Bordeaux Nord Aquitaine — Bordeaux, France Chu Dupuytren- Limoges — Limoges, France Institut Paoli-Calmettes — Marseille, France Centre Antoine Lacassagne — Nice, France View more locations Show fewer locations Loading locations... View Trial Details
Recruiting ctDNA-guided Treatment Decision-making NCT07394218 Conditions Breast Diseases, Breast Neoplasms, CtDNA, +5 more Locations Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China View Trial Details
Completed A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer NCT01268150 Conditions Breast Diseases, Breast Neoplasms, Locally Recurrent, +5 more Locations University of Miami — Miami, Florida, United States Augusta Oncology Associates — Augusta, Georgia, United States Central Georgia Cancer Care — Macon, Georgia, United States Northwest Georgia Oncology Centers, P.C. — Marietta, Georgia, United States View all 17 locations View more locations Show fewer locations Loading locations... View Trial Details
